Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Q In postmenopausal women at increased risk, what is the comparative efficacy and safety of raloxifene and tamoxifen for preventing invasive breast cancer?
Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Oncology ★★★★★★☆ Endocrine ★★★★★☆☆
randomised controlled trial.
blinded (clinicians, participants, and outcome assessors).*
Follow up period:
mean 3.9 years.
nearly 200 clinical centres in North America.
19 747 postmenopausal women ⩾35 years of age (mean age 59 y) whose 5 year predicted risk of breast cancer was ⩾1.66% (mean 4.03%) based on the Gail model. Exclusion criteria included recent hormone therapy use; stroke or venous thromboembolism (VTE) history; cancer in the previous 5 years; and uncontrolled atrial fibrillation, diabetes, or hypertension.
raloxifene, 60 mg/day (n = 9875), or tamoxifen, …